Showing results (1181-1190 of 1,373) with videos related to

Sort By:
Pageof 138
Physical Review Letters|February 4, 2014
Ultrafast short-range disordering of femtosecond-laser-heated warm dense aluminumP M Leguay, A Lévy, B Chimier, et al.
Blood|March 19, 2015
Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myelomaPhilippe Moreau, Brigitte Kolb, Michel Attal, et al.
Frontiers in Immunology|March 20, 2025
Corrigendum: Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS studyHeinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
The Journal of Urology|August 16, 2021
Contralateral Orchiopexy at the Time of Urgent Scrotal Exploration-Is It Safe? A Propensity Score Matched Analysis from the TORSAFUF CohortIgor Duquesne, Ugo Pinar, Van Thi Dang, et al.
Neurology and Therapy|July 4, 2025
Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS StudyHeinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Mycoses|July 28, 2022
Genotypic diversity and antifungal susceptibility of Scedosporium species from clinical settings in ChinaMin Chen, Xinlin Zhu, Yang Cong, et al.
Frontiers in Immunology|February 18, 2025
Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS studyHeinz Wiendl, Frederik Barkhof, Xavier Montalban, et al.
Cell Communication and Signaling : CCS|December 19, 2024
Transcriptional regulation of KCNA2 coding Kv1.2 by EWS::FLI1: involvement in controlling the YAP/Hippo signalling pathway and cell proliferationMaryne Dupuy, Anaïs Postec, Mathilde Mullard, et al.
National Science Review|June 26, 2026
A bird's-eye view for future ionic thermoelectrics: from ions to productsZiyao Xu, Mao Yu, Qikai Li, et al.
Annals of Hematology|June 10, 2023
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX studyM Macro, C Hulin, L Vincent, et al.
Pageof 138